Regulus notches another microRNA deal in pact with Biogen Idec

Fast on the heels of a $28 million partnership with AstraZeneca ($AZN), Regulus Therapeutics has struck again with another marquee microRNA pact--this time with Biogen Idec ($BIIB). The release doesn't spell out the upfront and milestone dollars attached to this deal, but Regulus will put its technology to work to find microRNA biomarkers for multiple sclerosis, a big franchise for the Biogen folk. "Utilizing innovative technology such as biomarkers can help us make more informed decisions earlier in clinical development and is key to our overall company strategy to enhance early-stage discovery efforts," said Steven Holtzman, Biogen's chief deal-maker. Release

Like what you're reading?
Click here to get more news like this delivered to your inbox everyday>>

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.